Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A

Journal of the Peripheral Nervous System

Volumn 13, Issue 1, 2008, Pages 64-70

  Padua, Luca ^a,b   Shy, Michael E ^c   Aprile, Irene ^b   Cavallaro, Tiziana ^d   Pareyson, Davide ^e   Quattrone, Aldo ^f   Rizzuto, Nicolo ^c   Vita, Giuseppe ^g   Tonali, Pietro ^a,b   Schenone, Angelo ^h  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VERONA   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

Author keywords

Charcot Marie Tooth type 1A; Neurophysiology; Quality of life

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; CHARCOT-MARIE-TOOTH DISEASE; COHORT STUDIES; ELECTROPHYSIOLOGY; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 40849092774     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00159.x     Document Type: Article

References (28)

1. Amadio PC (1993). Outcomes measurements. J Bone Joint Surg Am 75 : 1583 1584.
2. Apolone G, Mosconi P (1998). The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51 : 1025 1036.
3. Apolone G, Mosconi P, Ware JE (1997). Questionario sullo stato di salute SF-36. Manuale d'uso e guida all'interpretazione dei risultati. Guerini e Associati, Milano, Italy.
4. Berciano J, Gallardo E, Garcia A, Infante J, Mateo I, Combarros O (2006). Charcot-Marie-Tooth disease type 1A duplication with severe paresis of proximal lower limb muscles: a long-term follow-up study. J Neurol Neurosurg Psychiatry 77 : 1169 1176.
5. Campbell A (1976). Subjective measures of well-being. Am Psychol 31 : 117 124.
6. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, Palumbo PJ, Swanson CJ (1980). Human diabetic endoneurial sorbitol, fructose, and myoinositol related to sural nerve morphometry. Ann Neurol 8 : 590 596.
7. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ III., O'Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA, Service FJ, Rizza RA, Zimmerman BR (1991). The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 41 : 799 807.
8. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, Kamholz J, Shy ME (2000). Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 123 : 1516 1527.
9. Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, Yuki N (2001). Intravenous immunoglobulin therapy for Guillain-Barrè syndrome with IgG anti-GM1 antibody. Muscle Nerve 24 : 54 58.
10. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A, Patel PI (1991). DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66 : 219 232.
11. Medical Research Council (1976). Aids to examination of the peripheral nervous system. HMSO, London.
12. Nelis E, Van Broeckhoven C, De Jonghe P, Löfgren A, Vandenberghe A, Latour P, Le Guern E, Brice A, Mostacciuolo ML, Schiavon F, Palau F, Bort S, Upadhyaya M, Rocchi M, Archidiacono N, Mandich P, Bellone E, Silander K, Savontaus ML, Navon R, Goldberg-Stern H, Estivill X, Volpini V, Friedl W, Gal A (1996). Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 4 : 25 33.
13. Padua L, Schenone A, Aprile I, Benedetti L, Caliandro P, Tonali P, Orazio EN Italian NEUROPA Study Group (2005). Quality of life and disability assessment in neuropathy: a multicenter study. J Peripher Nerv Syst 10 : 3 10.
14. Padua L, Aprile I, Cavallaro T, Commodari I, La Torre G, Pareyson D, Quattrone A, Rizzato N, Vita G, Tonali P, Schenone A Italian CMT QoL Study Group (2006). Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicenter study. Neurol Sci 27 : 417 423.
15. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M (2004). Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10 : 396 401.
16. Raeymaekers P, Timmerman V, Nelis E, De Jonghe P, Hoogendijk JE, Baas F, Barker DF, Martin JJ, De Visser M, Bolhuis PA, Van Broeckhoven C (1991). Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1 : 93 97.
17. Russell JW, Karnes JL, Dyck PJ (1996). Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiological measurements. J Neurol Sci 135 : 114 117.
18. Sereda MW, Meyer Zu Horste G, Suter U, Uzma N, Nave KA (2003). Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9 : 1533 1537.
19. Shy ME, Rose MR (2005). Charcot-Marie-Tooth disease impairs quality of life: why? And how do we improve it? Neurology 65 : 790 791.
20. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M (2005). Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64 : 1209 1214.
21. Skre H (1974). Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 6 : 98 118.
22. Sorensen EJ, Daube JR, Windbank AJ (2006). Electrophysiological findings in a cohort of old polio survivors. J Peripher Nerv Syst 11 : 241 246.
23. Suter U, Snipes GJ (1995). Peripheral myelin protein 22: facts and hypotheses. J Neurosci Res 40 : 145 151.
24. Thomas PK, Marques W Jr., Davis MB, Sweeney MG, King RH, Bradley JL, Muddle JR, Tyson J, Malcolm S, Harding AE (1997). The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 120 : 465 478.
25. Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, Vermeulen M, de Visser M (2004). Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. J Neurol 251 : 1491 1497.
26. Vickrey BG, Hays RD, Beckstrand M (2000). Development of a health-related quality of life measure for peripheral neuropathy. Neurorehabil Neural Repair 14 : 93 104.
27. Vinci P, Serrao M, Millul A, Deidda A, De Santis F, Capici S, Martini D, Pierelli F, Santilli V (2005). Quality of life in patients with Charcot-Marie-Tooth disease. Neurology 65 : 922 924.
28. Ware JE Jr., Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36). I Conceptual framework and item selection. Med Care 30 : 473 483.